Plain-English translation of NCT07734493 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called LTX-001 to see if it can help people who are experiencing a sudden worsening or relapse of schizophrenia symptoms. Researchers want to understand whether the medication is safe to take, how the body processes it, and whether it helps reduce symptoms. Some participants will receive the actual medication while others will receive a placebo (an inactive pill) so researchers can compare how well the treatment works.
Current antipsychotic medications don't work well enough for everyone, and some people experience severe side effects. This trial is exploring whether this new medication could offer a safer or more effective option for people during acute episodes of schizophrenia.
You likely qualify if…
You likely don't qualify if…
You would stay at the study site for approximately five weeks (or up to seven weeks if you need time to stop taking previous medications). During your stay, you'll take either the new medication or a placebo by mouth once or twice daily, and researchers will regularly check your health through blood tests, heart monitoring, physical exams, and psychiatric assessments. You'll also complete various questionnaires and tests to measure your symptoms, mood, and how your body is responding to the treatment.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States